Meningococcal Vaccines, Industry, Pharmaceutical - Market Analysis 2016, Trend, Share, Growth, Forecast 2019
"PharmaPoint:
Meningococcal Vaccines - Global Drug Forecast and Market Analysis to
2025".
The Report covers current Market Trends, Analysis, Forecast, Review,
Share, Size, Growth, Effect.
Description-
Summary
Neisseria
meningitidis is a Gram-negative, encapsulated diplococcal bacterium
and is the causative agent for invasive meningococcal
disease. Although relatively rare around the globe, invasive
meningococcal disease is widely feared because of its high mortality
rate even in otherwise healthy individuals. The onset of invasive
meningococcal disease typically begins within three to seven days of
infection, but can occur as early as one day after infection. If left
untreated, meningococcal disease progresses rapidly. Even with
appropriate treatment, up to 10% of all cases still result in death
within 24 to 48 hours of symptom onset. This rapid onset and
progression of the disease emphasizes the need for a prophylactic
approach by vaccination.
Pharmaceutical
companies have developed vaccines addressing the most urgent medical
needs based on clinical efficacy and epidemiology. The resulting
vaccines can be divided into three categories, although other and
finer segmentations can be made. These three categories include
monovalent vaccines targeting serogroup C (MenC vaccines), vaccines
protecting against most serogroup B strains (MenB vaccines), and
tetravalent vaccines protecting against serogroups A, C, W, and Y
(MenACWY vaccines). While the MenB vaccines use recombinant proteins
as antigens, all other meningococcal vaccines are based on the
polysaccharide capsules of the various serogroups.
Highlights
Key
Questions Answered
-
Based on interviews with key opinion leaders (KOLs), GlobalData has
identified key unmet needs in the meningococcal vaccine marketplace.
-
What will be the effect of recent and upcoming changes in national
immunization schedules?
-
How will the new first-in-class vaccine covering all main serogroups
(MenABCWY) be received in the different markets?
-
What research and development (R&D) strategies will companies
leverage to compete in the future meningococcal vaccine marketplace?
-
Which patient population(s) are most likely to be targeted for
vaccines against serogroup B and the pentavalent MenABCWY pipeline
vaccine?
Key
Findings
-
GlobalData projects the meningococcal vaccine market in the US, 5EU,
Japan, and Brazil to grow from approximately $1.1bn in 2015 to $1.8bn
in 2025, at a compound annual growth rate (CAGR) of 5.4%. This growth
across the 8MM will primarily be driven by the introduction of
additional meningococcal vaccines into the national routine infant
and adolescent vaccination schedules in some 5EU countries. Further
growth will be the result of the launch of a pentavalent MenABCWY
vaccine during the forecast period while the commercial meningococcal
vaccine markets in Brazil and Japan will experience a decline at a
negative CAGR of 1.8% and 0.9% respectively.
-
With most countries in the 8MM using serogroup B vaccines only for
individuals at high risk of contracting meningococcal disease, the
routine application of these protein-based vaccines is seen as the
major unmet need to be addressed in the oncoming years.
-
GlobalData anticipates that opportunities will center on the
improvement of vaccine long-term efficacy whilst addressing the cost
effectiveness concerns voiced by various governmental institutions.
For
More Information Kindly Contact:
ResearchMoz
Global Pvt. Ltd.
90
State Street,
Albany,
NY 12207,
United
States
Blog
- http://bit.ly/2b1Ayn6
866-997-4948
(Us-Canada Toll Free),
+1-518-621-2074,
Email
to:
sales@researchmoz.us,
Comments
Post a Comment